International Meeting for Autism Research (London, May 15-17, 2008): TREATMENT AND REHABILITATION OF THE CHILDREN WITH PERVASIVE DEVELOPMENT DISODER AND SCHIZOPHRENIA

TREATMENT AND REHABILITATION OF THE CHILDREN WITH PERVASIVE DEVELOPMENT DISODER AND SCHIZOPHRENIA

Thursday, May 15, 2008
Champagne Terrace/Bordeaux (Novotel London West)
M. Igor , Department of Child, Adolescent Psychiatry and Medical-Social Rehabilitation, Ukrainian Research Institute of Social and Forensic Psychiatry and Drug Abuse, Kyiv, Ukraine
B. Yana , Department of Child, Adolescent Psychiatry and Medical-Social Rehabilitation, Ukrainian Research Institute of Social and Forensic Psychiatry and Drug Abuse, Kyiv 04080, Ukraine
M. Vladimir , Department of Child Neurology and Medical-Social Rehabilitation, National Medical Academy Postgraduated Education named by P.L.Shupik, Kyiv 04209, Ukraine
M. Inna , Department of Child, Adolescent Psychiatry and Medical-Social Rehabilitation, Ukrainian Research Institute of Social and Forensic Psychiatry and Drug Abuse, Kyiv 04108, Ukraine
Background: Pervasive development disorder (PDD) and schizophrenia (SCH)   is a neurodevelopment disorder that is associated with deficits in cognition, affect and social functioning. Research aim to study influence of risperidon therapy and medical - social rehabilitation on cognition and social functioning of the children. Objectives: We observed 93 patients in the age from 3 to18 years  ( 253 - with the PDD, 80 - SCH-spectrum disorders). Children were divided into 3 (variants / therapeutic) groups: a) on risperidon monotherapy, b) receiving sensory integration and cognitive-behavioural and social skills trainings, c) complex therapy: risperidon and rehabilitation. Methods: The efficacy of treatment in randomizate groop were analyzed using CGISS, PANSS, PEP-R, CARS, CANTAB, COGTEST and ILK test systems.
Results: Parameters of cognition in-group of children with PDD, receiving risperidon on a background of active rehabilitation were on the higher level, than in groups of comparison (P < 0,05). Cognition  in the greater degree influence to the level of social functioning at the PDD and early SCH, than negative symptoms of disorder. Long terminal therapy by risperidon raises efficiency of sensory integration and cognitive trainings for the children with PDD and severe cognition  and social reintegration at early demonstrating SCH. At long-term therapy of risperidon patients with  SCH on a background of active social rehabilitation with participation of family productive infringements, duration of disease and number of psychotic episodes in anamnesis, practically, did not influence a level of social functioning.  Conclusions: Early intervention may help prevent the often significant biological, social and psychological deterioration that can occur in the early years following onset of a psychotic disorder. Significant delays before effective treatment is initiated, or secondary morbidity resulting from aspects of management, can hamper preventive efforts. Potential benefits of early intervention include: reduced morbidity; more rapid recovery; better prognosis; preservation of psychosocial skills; preservation of family and social supports; decreased need for hospitalisation.
See more of: Treatment Posters 1
See more of: Poster Presentations